Product nameAnti-cardiac Troponin I (phospho S43) antibody
See all Cardiac Troponin I primary antibodies
DescriptionRabbit polyclonal to cardiac Troponin I (phospho S43)
SpecificityDetects endogenous levels of Troponin I only when phosphorylated at serine 43
Tested applicationsSuitable for: WB, ELISAmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic phosphopeptide derived from human cardiac troponin I around the phosphorylation site of serine 43 (S-A-SP-R-K).
- Jurkat Cells
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Concentration information loading...
PurityImmunogen affinity purified
Purification notesThe antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site
Our Abpromise guarantee covers the use of ab59420 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 30 kDa (predicted molecular weight: 24 kDa).|
FunctionTroponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
Involvement in diseaseDefects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Sequence similaritiesBelongs to the troponin I family.
- Information by UniProt
- cardiac muscle antibody
- Cardiac troponin I antibody
- cardiomyopathy, dilated 2A (autosomal recessive) antibody
All lanes : Anti-cardiac Troponin I (phospho S43) antibody (ab59420) at 1/500 dilution
Lane 1 : Jurkat cells
Lane 2 : Jurkat cells with blocking phosphopeptide
Predicted band size: 24 kDa
Observed band size: 30 kDa why is the actual band size different from the predicted?
This product has been referenced in:
- Yu ZY et al. RhoA/ROCK Signaling and Pleiotropic a1A-Adrenergic Receptor Regulation of Cardiac Contractility. PLoS One 9:e99024 (2014). WB ; Mouse . Read more (PubMed: 24919197) »
- Wang H et al. TNNI3K is a novel mediator of myofilament function and phosphorylates cardiac troponin I. Braz J Med Biol Res 46:128-37 (2013). Read more (PubMed: 23369981) »